Stefanie Mandl-Cashman

Title: Stefanie Mandl-Cashman: Innovator in Cancer Immunotherapy

Introduction

Stefanie Mandl-Cashman is a prominent inventor based in San Francisco, CA, known for her significant contributions to cancer immunotherapy. With a focus on developing innovative methods for identifying and treating cancer, she has been awarded 4 patents that showcase her expertise in the field.

Latest Patents

Her latest patents include groundbreaking work on compositions and methods for the identification of antigen-specific T cells. This patent discloses antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, along with methods for producing these complexes. Additionally, it outlines methods for creating libraries of comPACT polynucleotides and polypeptides, which are exemplary in capturing cancer neoepitope-reactive T cells with high accuracy. Another notable patent focuses on compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy. This includes compositions and methods for neoTCR-based cell therapy with a CD8 expression construct.

Career Highlights

Throughout her career, Stefanie has worked with notable companies such as Adoc Ssf, LLC and Pact Pharma, Inc. Her work has significantly advanced the understanding and treatment of cancer through innovative therapeutic approaches.

Collaborations

Stefanie has collaborated with esteemed colleagues, including Barbara Sennino and Alex Franzusoff, contributing to a dynamic research environment that fosters innovation in cancer treatment.

Conclusion

Stefanie Mandl-Cashman is a trailblazer in the field of cancer immunotherapy, with her patents reflecting her commitment to advancing medical science. Her work continues to inspire and pave the way for future innovations in cancer treatment.